Pharmaceutical polymeric nanoparticles prepared by the double emulsion-solvent evaporation technique

Recent Patents on Drug Delivery and Formulation

Volumn 6, Issue 3, 2012, Pages 224-235

  Piñón Segundo, Elizabeth ^a   Nava Arzaluz, María G ^b   Lechuga Ballesteros, David ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Laboratorio de Investigación y Posgrado en Tecnología Farmacéutica   (Mexico)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Double emulsion solvent evaporation technique; Drug delivery and imaging; Multifunctional nanoparticles; Nucleic acids; Peptides; Polymeric nanoparticles; Proteins; Vaccines

Indexed keywords

ALBUMIN; BRIMONIDINE; CARBOXYMETHYLCELLULOSE; CHLOROFORM; CISPLATIN; CURCUMIN; DAUNORUBICIN; DICHLOROMETHANE; DOXORUBICIN; EFAVIRENZ; FLUOROURACIL; GELATIN; HEPATITIS B SURFACE ANTIGEN; LOPINAVIR; MACROGOL; NANOPARTICLE; ORGANIC SOLVENT; PACLITAXEL; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYGLACTIN; POLYMER; POLYSORBATE 60; POLYVINYL ALCOHOL; POVIDONE; RITONAVIR; SMALL INTERFERING RNA; SORBITAN STEARATE; STAUROSPORINE; UNINDEXED DRUG;

BIODEGRADABILITY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; EVAPORATION; HYDROPHILICITY; NANOEMULSION; NANOENCAPSULATION; NANOTECHNOLOGY; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SPRAY DRYING;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EMULSIONS; HUMANS; NANOPARTICLES; PARTICLE SIZE; PATENTS AS TOPIC; POLYMERS; SOLVENTS;

EID: 84867823875     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221112802652606     Document Type: Review

References (80)

1. Vanderhoff, J.H., El-Aasser, M.S., Ugelstad, J. Polymer emulsification process. US4177177 (1979).
2. Bhavna MA, Baboota S, Javed A. Patents on nanoparticulate drug delivery systems-a review. Rec Pat Drug Deliv Formul 2008; 2(1): 83-9.
3. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1-20.
4. Lassalle V, Ferreira ML. PLA nano-and microparticles for drug delivery: An overview of the methods of preparation. Macromol Biosci 2007; 7: 767-83.
5. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011; 63(3): 170-83
6. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 2007; 120: 2527-37.
7. Zolnic BS, Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev 2009; 61(6) 422-7.
8. des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release 2006; 116(1):1-27.
9. Lambert G, Fattal E, Couvreur P. Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv Drug Deliv Rev 2001; 47(1): 99-112.
10. Rao JP, Geckeler KE. Polymer nanoparticles: Preparation techniques and size-control parameters. Prog Polym Sci 2011; 36: 887-913.
11. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009; 26(5):1025-58.
12. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods of drug-loaded polymeric nanoparticles. Nanomedicine 2006; 2: 8-21.
13. Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 1998; 24(12): 1113-28.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Impurities: Guideline for Residual Solvents Q3C(R5). Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Gui delines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf. (Accesed on: April 15, 2012).
15. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010; 75: 1-18.
16. Tewes F, Munnier E, Antoon B, Okassa LN, Cohen-Jonathan S, Marchais H, et al. Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur J Pharm Biopharm 2007; 66: 488-92.
17. Yuan H, Jiang SP, Du YZ, Miao J, Zhang XG, Hu FQ. Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles. Colloids Surf B Biointerfaces 2010; 75: 1-18.
18. Prasad S, Cody V, Saucier-Sawyer JK, Saltzman WM, Sasaki CT, Edelson RL, et al. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine: NBM 2011; 7:1-10.
19. Vrignaud S, Benoit JP, Staulnier P. Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. Biomaterials 2011; 32: 8593-604.
20. Singh MR, Singh D, Saraf S. Formulation and optimization of controlled delivery system for antihypertensive peptide using response surface methodology. Am J Drug Discov Dev 2011; 1(3): 174-87.
21. Mohanraj VJ, Chen Y. Nanoparticles-A Review. Trop J Pharm Res 2006; 5(1): 561-73.
22. Bilati U, Allémann E, Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nanoand microparticles. Eur J Pharm Biopharm 2005; 59: 375-88.
23. Khoee S, Sattari, A. Atyabi, F. Physico-chemical properties investigation of cisplatin loaded polybutyladipate (PBA) nanoparticles prepared by w/o/w. Mater Sci Eng C Mater Biol Appl 2011; doi:10.1016/j.msec.2011.09.005
24. Khoee S, Hossainzadeh MT. Effect of O/S/W process parameters on 17β-EV loaded nanoparticles properties. Colloids Surf B Biointerfaces 2010; 75: 133-40.
25. Yuan W, Wu F, Guo M, Jin T. Development of protein delivery microsphere system by a novel S/O/O/W multi-emulsion. Eur J Pharm Sci 2009; 36: 212-8.
26. Andreas K, Zehbe R, Kazubek M, Grzeschik K, Sternberg N, Bäumler H, Schubert H, Sittinger M, Ringe J. Biodegradable insulin-loaded PLGA microspheres fabricated by three different emulsification techniques: Investigation for cartilage tissue engineering. Acta Biomater 2011; 7: 1485-95.
27. Kalombo, L. Nanoparticle carriers for drug administration and process for producing same. US20110033550 (2011).
28. Nandiyanto ABD, Okuyama K. Progress in developing spraydrying methods for the production of controlled morphology particles: From the nanometer to submicrometer size ranges. Adv Powder Technol 2011; 22: 1-19.
29. Bowey K, Neufeld RJ. Systemic and mucosal delivery of drugs within polymeric microparticles produced by spray drying. Bio Drugs 2010; 24(6): 359-77.
30. Hageman MJ. The role of moisture in protein stability. Drug Dev Ind Pharm 1988; 14(14): 2047-70.
31. Hanes, J., Edwards, D.A., Evora, C., Langer, R. Particles incorporating surfactants for pulmonary drug delivery. USRE37053E (2001).
32. Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, et al. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release 1998; 50(1-3): 31-40.
33. Piñón-Segundo E, Ganem-Quintanar A, Garibay-Bermúdez JR, Quintanar-Guerrero D. Preparation of nanoparticles by solvent displacement using a novel reflux system. Pharm Dev Tech 2006; 11: 493-501.
34. Jimenez N, Galan J, Vallet A, Egea MA, Garcia ML. Methyl trypsin loaded poly(D, L-lactide-coglycolide) nanoparticles for contact lens care. J Pharm Sci 2010; 99(3):1414-26.
35. Mohamed F, Van Der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 2008; 97(1):71-87.
36. Van deVen H, Vermeersch M, Matheeussen A, Vandervoort J, Weyenberg W, Apers S, et al. PLGA nanoparticles loaded with the antileishmanial saponin β-aescin: Factor influence study and in vitro efficacy evaluation. Int J Pharm 2011; 420: 122-32.
37. Feczkó T, Tóth J, Dósa Gy, Gyenis J. Influence of process conditions on the mean size of PLGA nanoparticles. Chem Eng Process 2011; 50: 846-53.
38. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-Eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech 2011; 12(4): 1087-101.
39. Cun D, Foged C, Yang M, Frøkjær S, Nielsen HM. Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm 2010; 390: 70-5.
40. Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, Scurr D, et al. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization. Eur J Pharm Biopharm 2011; 77: 26-35.
41. Mahdavi H, Mirzadeh H, Hamishehkar H, Jamshidi A, Fakhari A, Emami J, et al. The effect of process parameters on the size and morphology of poly(D, L-lactide-co-glycolide) micro/nanoparticles prepared by an oil in oil emulsion/solvent evaporation technique. J Appl Polymer Sci 2010; 116:528-34.
42. Kristl, J., Ahlin, P., Cegnar, M., Vrecer, F., Kos, J. Process for the production of nanoparticles, wherein low mechanical and sonic energies are used simultaneously. WO03099262A1 (2003).
43. Braden, A.R.C., Vishwanatha, J.K., Kafka, E. Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics. US20080253961 (2008).
44. Lins, D.F.M. Pharmaceutical compositions of nanoparticles containing active ingredients. US20110118364 (2011).
45. Gurny, R., Peppas, N.A., Harrington, D.D., Banker, G.S. Development of biodegradable and injectable latices for controlled release of potent drugs. Drug Dev Ind Pharm 1981; 7(1): 1-25
46. Lu X-Y, Zhang Y, Wang L. Preparation and in vitro drug-release behavior of 5-fluorouracil-loaded poly(hydroxybutyratecohydroxyhexanoate) nanoparticles and microparticles. J Appl Polym Sci 2010; 116(5): 2944-50.
47. Destache, C.J., Nanoparticles and methods of use. US20110236437 (2011).
48. Kreuter, J., Gelperina, S., Maksimenko, O., Khalanskiy, A. Polylactide nanoparticles. US8003128 (2011).
49. Fidanboylu, M., Papanicolau, I. Encapsulation of biologically active agents. US20110059167 (2011).
50. Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 2010; 138: 843-53.
51. Liu J, Qiu Z, Wang S, Zhou L, Zhang S. A modified doubleemulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity. Biomed Mater 2011; 5:065002
52. Luo G, Yu X, Jin C, Yang F, Fu D, Long J, et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 2010; 385(1-2): 150-6.
53. Thomas C., Gupta V, Ahsan F. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm 2010; 379: 41-50.
54. Florindo HF, Pandit S, Lacerda L, Gonçalves LMD, Alpar HO, Almeida AJ. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-ε-caprolactone-based nanoparticles. Biomaterials 2009; 30: 879-91.
55. Kim BS, Kim CS, Lee KM. The intracellular uptake ability of chitosan-coated poly (D, L-lactide-co-glycolide) nanoparticles. Arch Pharm Res 2008; 31(8): 1050-4.
56. Park YM, Shin BA, Oh Ij. Poly(L-lactic acid)/polyethylenimine nanoparticles as plasmid DNA carriers. Arch Pharm Res 2008; 31(1): 96-102.
57. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm 2009; 367: 195-203.
58. Yang J, Zeng Y, Li Y, Song C, Zhu W, Guan H, et al. Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis. Eur J Pharm Sci 2008; 23: 427-34.
59. Hanes, J., Fu, J., Fiegel, J. Biodegradable polymer compositions, compositions and uses related thereto. US7163697B2 (2007).
60. Lavik, E., Bertram, J., Saluja, S., Kuehn, M., Kwon, Y.H., Robinson, R., Huang, J.J. Sustained delivery of drugs from biodegradable polymeric microparticles. US20110206773 (2011).
61. Ahlemim, M., Ausborn, M., Bodmer, D., Schoch, C. Ophthalmic depot formulations for periocular or subconjunctival administration. US20040234611 (2004).
62. Kreuter, J., Gelperina, S., Maksimenko, O., Khalanskiy, A. Polylactide nanoparticles. US8003128 (2011).
63. Destache, C.J. Nanoparticles and methods of use. US20110236437 (2011).
64. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J Control Rel 2008; 125: 193-209.
65. Ng SM, Choi JY, Han HS, Huh JS, Lim JO. Novel microencapsulation of potential drugs with low molecular weight and high hydrophilicity: Hydrogen peroxide as a candidate compound. Int J Pharm 2010; 384: 120-7.
66. Ungaro F, Giovino C, Coletta C, Sorrentino AM, Quaglia F. Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur J Pham Sci 2010; 41: 60-70.
67. Muzykantov, V.R., Dziubla, T. Antioxidant Polymer nanocarriers for use in preventing oxidative injury. US7597907 (2009).
68. Simone, E., Muzykantov, V.R., Dziubla, T.D. Method and compositions for polymer nanocarriers containing therapeutic molecules. US7927629 (2011).
69. Turnell, W.G., Li, H., Gomurashvili, Z.D., Katsarava, R. Polymer particle delivery compositions and methods of use. US20060177416A1 (2006).
70. Gomurashvili, Z.D., Landis, G., Hong, L., Turnell, W.D., Defife, K., Vassilev, V.P., Yuan, YNMN. Polymer particles for delivery of macromolecules and methods of use. WO2008048298 (2008).
71. Chu, C.C., Katsarava, R., Gomurashvili, Z.D., Turnell, W.G. Oligo-ethylene glycol-based polymer compositions and methods of use. US20110027379 (2011).
72. Hossainy, S.F.A., Simhambhatla, M.V. Stent coatings incorporating nanoparticles. US20070110787 (2007).
73. Hossainy, S.F.A., Ludwig, F.N., Sridharan, S. Nanoparticle releasing medical devices. WO 2008024131 (2008).
74. Osterhout, D.J., Hasenwinkel, J.M., Stelzner, D.J. Nanosphere/ microsphere delivery system for the treatment of spinal cord injury. US20110212136 (2011).
75. Wang, Y.C., Wu, Y.T., Yang, C.S. Controlled release multidrug formulations for spinal cord injury. US20110052711 (2011).
76. Carlsson, H., Larsson A., Söderlind, E. Polymer particle vaccine delivery system. WO9952550 (1999).
77. Carlsson H., Larsson A., Söderlind E. Antigen delivery system and method of production. US6838089 (2005).
78. Wittum-Hudson, J., Hudson, A.P. Genus-wide chlamydial peptide vaccine antigens. US2011 0236484 (2011).
79. Chung, B.H., Lim, Y.T., Han, J.H. Polymer particles for NIR/MR bimodal molecular imaging and method for preparing the same. US20110212032 (2011).
80. Xu, R., Roberts, C., Zhang, L. Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders. US20110104069 (2011).